echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The market of 600 million ushered in the approval of the new dosage form of Heyi Pharmaceutical's lidocaine hydrochloride ophthalmic gel

    The market of 600 million ushered in the approval of the new dosage form of Heyi Pharmaceutical's lidocaine hydrochloride ophthalmic gel

    • Last Update: 2022-04-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      On March 24, the official website of the State Food and Drug Administration showed that the lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical was approved for marketing, which was the first lidocaine ophthalmic gel in China
    .
    According to data from Minet.
    com, in 2020, the sales of terminal lidocaine in China's public medical institutions exceeded 600 million yuan

    .
     
     
      Lidocaine hydrochloride amide local anesthetics have obvious bidirectional effects of excitation and inhibition on the central nervous system, mainly used for infiltration anesthesia, epidural anesthesia, surface anesthesia, nerve conduction block,
    etc.
     
      According to data from Minet.
    com, in 2020, the sales of terminal lidocaine in China's urban public
    hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan, and the sales in the first half of 2021 increased year-on-year.
    37.
    17%

    .
     
      At present, lidocaine hydrochloride dosage forms include injections, gels, patches and aerosols, among which the market share of injections is close to 80%.
    There
    are more than 30 companies
    with production approvals for this dosage form.
    has exceeded 100 million yuan

    .
    In terms of gel formulations, five companies, Kangye, Kangde, Jianneng, Jichuan and Zizhu, have obtained production approvals

    .
    In addition, only Tide has been approved for plaster, and only Xiangxue and Shanghai Pharma Xinyi have been approved for aerosol

    .
     
      Dosage forms of lidocaine hydrochloride in Chinese public medical institutions in the first half of 2021 (unit: ten thousand yuan)
      Source: Minet.
    com China's public medical institutions terminal competition pattern
     
      The lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical is the first approved lidocaine ophthalmic gel in China.
    The lidocaine hydrochloride ophthalmic gel is mainly used for surface anesthesia in various ophthalmic surgeries and ophthalmic examinations.

    .
    Before Sichuan Heyi Pharmaceutical, only the original research products of Akron Pharmaceuticals (AKORN) were approved for marketing in the world

    .
     
      Driven by the centralized procurement of intraocular lenses, the volume of ophthalmic surgeries will increase in the future, and the ophthalmic gel formulation market is expected to usher in a large volume
    .
     
      Data source: Minet database, company announcement
      On March 24, the official website of the State Food and Drug Administration showed that the lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical was approved for marketing, which was the first lidocaine ophthalmic gel in China
    .
    According to data from Minet.
    com, in 2020, the sales of terminal lidocaine in China's public medical institutions exceeded 600 million yuan

    .
     
     
      Lidocaine hydrochloride amide local anesthetics have obvious bidirectional effects of excitation and inhibition on the central nervous system, mainly used for infiltration anesthesia, epidural anesthesia, surface anesthesia, nerve conduction block,
    etc.
     
      According to data from Minet.
    com, in 2020, the sales of terminal lidocaine in China's urban public
    hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan, and the sales in the first half of 2021 increased year-on-year.
    37.
    17%

    .
     
      At present, lidocaine hydrochloride dosage forms include injections, gels, patches and aerosols, among which the market share of injections is close to 80%.
    There
    are more than 30 companies
    with production approvals for this dosage form.
    has exceeded 100 million yuan

    .
    In terms of gel formulations, five companies, Kangye, Kangde, Jianneng, Jichuan and Zizhu, have obtained production approvals

    .
    In addition, only Tide has been approved for plaster, and only Xiangxue and Shanghai Pharma Xinyi have been approved for aerosol

    .
     
      Dosage forms of lidocaine hydrochloride in Chinese public medical institutions in the first half of 2021 (unit: ten thousand yuan)
      Source: Minet.
    com China's public medical institutions terminal competition pattern
     
      The lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical is the first approved lidocaine ophthalmic gel in China.
    The lidocaine hydrochloride ophthalmic gel is mainly used for surface anesthesia in various ophthalmic surgeries and ophthalmic examinations.

    .
    Before Sichuan Heyi Pharmaceutical, only the original research products of Akron Pharmaceuticals (AKORN) were approved for marketing in the world

    .
     
      Driven by the centralized procurement of intraocular lenses, the volume of ophthalmic surgeries will increase in the future, and the ophthalmic gel formulation market is expected to usher in a large volume
    .
     
      Data source: Minet database, company announcement
      On March 24, the official website of the State Food and Drug Administration showed that the lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical was approved for marketing, which was the first lidocaine ophthalmic gel in China
    .
    According to data from Minet.
    com, in 2020, the sales of terminal lidocaine in China's public medical institutions exceeded 600 million yuan

    .
     
     
      Lidocaine hydrochloride amide local anesthetics have obvious bidirectional effects of excitation and inhibition on the central nervous system, mainly used for infiltration anesthesia, epidural anesthesia, surface anesthesia, nerve conduction block,
    etc.
     
      According to data from Minet.
    com, in 2020, the sales of terminal lidocaine in China's urban public
    hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan, and the sales in the first half of 2021 increased year-on-year.
    37.
    17%

    .
    hospital hospital hospital
     
      At present, lidocaine hydrochloride dosage forms include injections, gels, patches and aerosols, among which the market share of injections is close to 80%.
    There
    are more than 30 companies
    with production approvals for this dosage form.
    has exceeded 100 million yuan

    .
    In terms of gel formulations, five companies, Kangye, Kangde, Jianneng, Jichuan and Zizhu, have obtained production approvals

    .
    In addition, only Tide has been approved for plaster, and only Xiangxue and Shanghai Pharma Xinyi have been approved for aerosol

    .
    enterprise enterprise enterprise
     
      Dosage forms of lidocaine hydrochloride in Chinese public medical institutions in the first half of 2021 (unit: ten thousand yuan)
      Source: Minet.
    com China's public medical institutions terminal competition pattern
     
      The lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical is the first approved lidocaine ophthalmic gel in China.
    The lidocaine hydrochloride ophthalmic gel is mainly used for surface anesthesia in various ophthalmic surgeries and ophthalmic examinations.

    .
    Before Sichuan Heyi Pharmaceutical, only the original research products of Akron Pharmaceuticals (AKORN) were approved for marketing in the world

    .
     
      Driven by the centralized procurement of intraocular lenses, the volume of ophthalmic surgeries will increase in the future, and the ophthalmic gel formulation market is expected to usher in a large volume
    .
     
      Data source: Minet database, company announcement
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.